Another myristoyl-CoA analogue, B13, also known as D-NMAPPD, potently inhibited NMT1 enzymatic activity against prostate cancer cells.199 By competing with the myristoyl-CoA binding site of NMT1, B13 impaired the myristoylation of Src, leading to the blocking of relevant oncogenic signalling and thereby promoting the antitumour effect. Here, NMT1 is linked to Familial prostate cancer.